StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

Arcutis Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Arcutis Biotherapeutics's price to sales ratio was 7.7× on Nov 11, 2026, against 11.6× a year earlier. Over the last 4 years it ranged from 2.3× to 267.9×, with a median of 9.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.7×−3.3
2025Dec 31, 202511.0×−0.8
2024Dec 31, 202411.8×+7.7
2023Dec 29, 20234.1×–

More Arcutis Biotherapeutics figures

See a number that looks wrong?